EP1551334A2 - Dispositif medical permettant l'apport intraluminal d'agents pharmaceutiques - Google Patents

Dispositif medical permettant l'apport intraluminal d'agents pharmaceutiques

Info

Publication number
EP1551334A2
EP1551334A2 EP03757429A EP03757429A EP1551334A2 EP 1551334 A2 EP1551334 A2 EP 1551334A2 EP 03757429 A EP03757429 A EP 03757429A EP 03757429 A EP03757429 A EP 03757429A EP 1551334 A2 EP1551334 A2 EP 1551334A2
Authority
EP
European Patent Office
Prior art keywords
vip
vasodilator
drug
restenosis
blood flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03757429A
Other languages
German (de)
English (en)
Other versions
EP1551334A4 (fr
Inventor
Leo Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1551334A2 publication Critical patent/EP1551334A2/fr
Publication of EP1551334A4 publication Critical patent/EP1551334A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Definitions

  • the present invention relates to devices for intra-lumenal drug delivery.
  • the devices are particularly useful for local delivery of therapeutic substances such as chemotherapeutics, platelet inhibitors, smooth muscle inhibitors and vasodilators.
  • therapeutic substances can be used in treating restenosis, pulmonary hypertension and other circulatory disorders.
  • the device is coated or impregnated with the pharmaceutical substance and can be permanent or biodegradable.
  • Stenosis is the narrowing of the blood vessel lumen.
  • stenosis of cardiac circulation can lead to acute infarction with subsequent ischemia
  • Stenosis is frequently treated with angioplasty.
  • Neointimal formation after stent implantation can cause luminal narrowing called restenosis.
  • Restenosis is induced by initial platelet adhesion and thrombus formation followed by immunocytic adhesion on the stent surface and injured vessel wall. The thrombus then releases factors that activate the proliferation of smooth muscle cells.
  • PTA percutaneous tra ⁇ sluminal angioplasty
  • Restenosis is believed to arise through the proliferation and migration of smooth muscle cells arterial wall, as well as through geometric changes in the arterial wall referred to as "remodeling.” It has similarly been postulated that the delivery of appropriate agents directly into the arterial wall could interrupt the cellular and/or remodeling events leading to restenosis. However, the results of attempts to prevent restenosis in this manner have been mixed.
  • a device such as an intravascular stent can be a useful adjunct to PTA particularly in the case of either acute or threatened closure after angioplasty. The stent is placed in the dilated segment of the artery to mechanically prevent abrupt closure and restenosis.
  • a stent is an inserted mesh of wires that stretch and mold to the arterial wall to prevent reocclusion.
  • the arterial and coronary artery stents have made progressive structural improvements leading to the evolution of third generation stents or coated stents. Stents are described for instance in US Patent Nos. 6,235,053; 6,165,209; 6,129,725; 6,241,760; and 6,197,047.
  • Implantable medical devices capable of delivering medicinal agents have been described.
  • Several patents are directed to devices utilizing biodegradable or bioresorbable polymers as drug containing and releasing coatings, including US
  • Patent Nos. 4,916,193; 4,994,071; and 6,096,070 are directed to the formation of a drug containing hydrogel on the surface of an implantable medical device, these include US Patent Nos. 5,221,698; and 5,304,121. Still other patents describe methods for preparing coated intravascular stents.
  • US Patent No. 5,464,650 describes coating stents via application of polymer solutions containing dispersed therapeutic material to the stent surface followed by evaporation of the solvent.
  • US Patent No. 6,099,561 describes stents with ceramic-like coatings.
  • 6,231,600 describes stents with hybrid r ⁇ atings including a time released restenosis inhibiting coating and a non-thrombogenic coating to prevent clotting on the device.
  • US Patent No. 6,214,901 describes a biocompatible polymer suitable for coating implantable medical devices and delivering therapeutics suspended therein Additional coatings for medical devices are described for instance in US Patent Nos. 6,071,305; 6,179,817; and 6,218,016.
  • Several therapeutic agents have been proposed for treating or preventing restenosis.
  • US Patent No. 6,214,868 describes preventing or treating coronary restenosis which comprises administering an effective amount of a catechin, derived from a green tea extract.
  • Pulmonary hypertension has been an enigma to the medical profession both diagnostically and therape ⁇ tically. Its well known “mirror image cousin,” arterial hypertension is probably the most diagnosed and treated medical condition, while this poor relation remains undiagnosed, untreated and quietly deadly. Unlike arterial hypertension, pulmonary hypertension can not be readily diagnosed such as by a sphygmomanometer. Pulmonary hypertension is defined when the pressure in the pulmonary artery exceeds 25 mm of mercury at rest or 30 mm of mercury during exercise. There are two forms or pulmonary hypertension. One is known as primary pulmonary hypertension where the cause is unknown and second form is referred to as secondary pulmonary hyertension, meaning that it is secondary to another identifiable underlying cause.
  • Pulmonary hypertension usually occurs in young adults, with a mean age of 45, varying from 15 to 66 years of age. Approximately 62% are female. The median survival time after diagnosis is approximately 2.5 years. Secondary pulmonary hypertension can result from a multitude of diseases including cardiac problems such as sever mitral stenosis, severe aortic stenosis, left to right shunts (VSD), congestive heart failure, diastolic dysfunction, to list a few of the cardiac causes. Other causes are obstructive sleep apnea, chronic pulmonary emboli, pulmonary parenchymal disease such as emphysema, pulmonary fibrosis or chest wall deformities. It also occurs in connective tissue disease e.g.
  • lupus erythematosus polymiositis, rheumatoid arthritis, scleroderma and with the CREST syndrome.
  • Secondary pulmonary hypertension has been associated with portal hypotension, and with the use of appetite suppressants. Elevated pulmonary artery pressure has been found to be a specifically significant prognostic factor in chronic obstructive pulmonary disease patients receiving long term oxygen therapy. In a recent study at the University Hospital in France, Oswald-Mammosser and co-workers found that the five year survival in patient's with severe COPD with normal resting pulmonary artery pressure was 62% and in patients with elevated pulmonary artery pressure the survival was only 36%.
  • the means of treatment for primary or secondary pulmonary hypertension are medical or surgical.
  • VIP vasoactive intestinal peptide
  • Surgery for treatment of pulmonary hypertension usually consists of lung transplantation, single, bilateral or heart with bilateral lung. Most patients have a waiting period of two to three years for an appropriate donor, obviating the need for many who succumb to pulmonary hypertension. Survival at five years post- transplantation is 37-44%. At present it does not appear to be a viable treatment. The lung volume reduction procedure remains a questionable option for COPD. Cancer In spite of numerous advances in medical research, cancer remains the second leading cause of death in the United States. In the industrialized countries, roughly one in five persons will die of cancer. Traditional modes of clinical care, such as surgical resection, radiotherapy and chemotherapy, have a significant failure rate, especially for solid tumors.
  • Neoplasia resulting in benign tumors can usually be completely cured by removing the mass surgically. If a tumor becomes malignant, as manifested by invasion of surrounding tissue, it becomes much more difficult to eradicate. Once a malignant tumor metastasizes, it is much less likely to be eradicated.
  • the three major cancers, in terms of morbidity and mortality, are colon, breast and lung. New surgical procedures offer an increased survival rate for colon cancer.
  • Lung cancer remains largely refractory to treatment. Excluding basal cell carcinoma, there are over one million new cases of cancer ⁇ per year in the United States alone, and cancer accounts for over one half million deaths per year in this country. In the world as a whole, the five most common cancers are those of lung, stomach, breast, colon/rectum, and uterine cervix, and the total number of new cases per year is over 6 million. Only about half the number of people who develop cancer die of it. Vasodilators
  • Vasodilators cause vasodilation of or in increased rate of blood flow through the arteries. Thus, upon administration of VIP and or NP, vasodilation or rate of blood flow would be expected to increase.
  • VIP is a basic, linear 28 amino acid polypeptide isolated initially form porcine duodenum (Mutt et al. (1974) Eur. J. Biochem. 42:581-589) and widely found in the central and peripheral nervous systems and digestive tract. VTP has strong vasodilating properties and hypotensive activity and systemic vasodilatory activity. Administered intravenously (TV) or directfy into the heart, VIP increases heart rate and contractile force. Anderson et al. (1988) X Cardio. Pharmacol. 12:365-371; Rigel et al (1988) Am J. Physiol. 255.H317-319; Karasawa et al. (1990) Eur. J. Pharmacol. 187:9-17; and Unverferth et al. (1985) X Laboratory. Clin. Med. 106:542-550.
  • VTP is considered to be a peptide hormone belonging to the glucagons-secretin family.
  • Other members of this family of structurally related peptides include gastric inhibitory peptide (GIP), growth hormone releasing factor (GHRF) and adenylate cyclase-activating peptide (PACAP).
  • GIP gastric inhibitory peptide
  • GHRF growth hormone releasing factor
  • PACAP adenylate cyclase-activating peptide
  • VIP is derived by proteolytic cleavage from a larger precursor molecule.
  • the 170 amino acid precursor preproVIP contains histidine isoleucine, another biologically active peptide. Itoh et al. (1983) Nature 304:547-549.
  • VIP contains at least two functional regions: a region of receptor-specific binding and a region involved in biological activity. Gozes et al. (1989) Mol. Neurobiol. 3:201-236. VIP mediates or modulates several basic cell functions. These include brain activity, endocrine functions, cardiac activity, respiration, digestion and sexual potency. The widespread physiologic distribution of VIP correlates with its involvement in a broad spectrum of biological activities. The actions of VIP are of a complex nature, encompassing receptor modulation, inducting release of neurotrophic _ factors, neurotransrrrission and neuromodulation. VIP occurs widely in the central and peripheral nervous systems and digestive tract, and may play a role in parasympathetic responses in the trachea and gastrointestinal tract.
  • VIP is an important modulator of cell growth, differentiation and survival during development of the sympathetic nervous system VIP acts as a neuromodulator in several responses.
  • VTP has a selective effect on muscarioic excitation in sympathetic ganglia with no apparent effect on ni ⁇ tinic responses, indicating that VIP has intrinsic properties affecting electrical activity and also interacts with other neurotransmitter systems to modulate physiologic responses.
  • VIP has been found in glial cells and appears to be of physiological importance. VIP mediates communication between neurons and glia, a relationship of fundamental importance to neurodevelopment and function. VTP immunoreactive fibers are present in and appear to be intrinsic to the canine heart. Weihe et al. (1981) Neurosci. Let. 26:283-288; and Weihe et al. (1984) Cell Tiss. Res. 236:527-540. VIP-containing neurons are present in canine hearts where VIP exerts a strong global myocardial effect similar to, but more sustained than, the adrenergic effect. The effect is qualitatively similar to other inotropic drugs that act through specific cell surface membrane receptors coupled to ade ⁇ ylate cyclase, for example ⁇ -adrenergic agonists such as proterenol.
  • VIP receptors are found in both canine and human hearts, thus canines are an appropriate model for VIP in humans.
  • Vagal, efferent stimulation of ⁇ -blocked, atropinized dogs increased heart rate and contractile force, an effect that may be due to the release of VIP.
  • VIP is released from dog atria when parasympathetic nerves are stimulated. Hill et al. (1993) X Auton. Nerv. Sys. 43: 117-122; and Hill et al. (1995).
  • Many different potential therapeutic uses of VIP, VIP analogues and VlP-like polypeptides have been proposed.
  • VIP analogues and VIP-like peptides Due to the widespread distribution and variety of activities of VTP, VIP analogues and VIP-like peptides have been proposed as treatment for various conditions including, among others, asthma and erectile dysfunction.
  • VIP is active when present in amounts of only picograms, and is stable in solution. This makes it particularly suited for use in a medicinal context.
  • VIP has inotropic and chronotropic effects due to its vasodilatory properties.
  • VIP acts as a bronchodilator and a relaxant of pulmonary vascular smooth muscle.
  • the inotropic state of the ventricle may be affected by the activation of several receptors, some of which are coupled to adenylate cyclase. Foremost among these is the ⁇ -adrenergic receptor, which, when activated by its corresponding neurotransmitter norepinephrine, mediates increased cardiac contractility.
  • VIP is a potentially important agonist because it is present in nerve fibers in the heart, is coupled to adenylate cyclase, and, when administered IV, mediates both increased contractility and coronary vasodilation. There is some evidence that VIP has two discrete binding sites specific to the central nervous system
  • the time-course of chronotropic effects of VIP is dose-dependent; however the time-course for recovery from inotropic effects is not. This may be due to variation in neurotransmitter levels in extracellular spaces, occurring due to heart movement. At a constant level of sympathetic nerve stimulation, dogs whose hearts were paced at different rates showed different recovery times from the inotropic response. Thus the recovery from VIP inotropic effects is affected by heart rate, which in turn is altered by the chronotropic effects.
  • the inotropic and chronotropic effects of VIP are therefore related but do not occur through the same mechanism There may be different receptors for the two responses or the biochemical cascade initiated differs for the two.
  • Intact endothelium is necessary to achieve vascular relaxation in response to acetylcholine.
  • the endothelial layer modulates autonorrric and hormonal effects on the contractility of blood vessels.
  • endothelial cells In response to vasoactive stimuli, endothelial cells - release short-lived vasodilators called endothelium-derived relaxing factor (EDRF) or endothelium-derived contracting factor.
  • EDRF endothelium-derived relaxing factor
  • Endothelial cell-dependent mechanisms are important in a variety of vascular beds, including the coronary circulation.
  • VTP The natural properties of VIP have been improved.
  • the C-teiminus holds a receptor recognition site, and the N-terminus holds the activation site with minimal binding capacity.
  • Peptides non-essential to function have been manipulated and altered, resulting in some cases in increased levels of activity over natural VIP.
  • These VIP analogues and VTP-like peptides can be utilized in any situation where VIP is effective.
  • Some VIP analogues have improved storage properties and increased duration of action, and therefore may be superior drugs.
  • VTP antagonists alter VIP function. US Patent No. 5,217,953.
  • VTP VTP-binding protein
  • mRNA for this VTP has been found in several tissues including liver, lung, intestine and brain.
  • mRNA for another VIP receptor has been found in stomach, testes and brain.
  • the VIP receptor or receptors may be coupled to adenylate cyclase, as a VTP- stimulated adenylate cyclase has been identified in various areas of the central nervous system as well as the liver and pituitary.
  • adenylate cyclase has been identified in various areas of the central nervous system as well as the liver and pituitary.
  • Studies of rat sensory neurons show that VIP transcription may be increased via activation of cellular transcription factors that bind to a cyclic adenosine monophosphate (cAMP) responsive element.
  • cAMP cyclic adenosine monophosphate
  • VIP action on cAMP may be mediated via G-proteins, signal transducers that stimulate hydrolysis of GTP to GDP, as GTP and its analogues inhibit VIP-receptor binding and potentiate cAMP synthesis in response to VIP. Paul (1989) Biochem Pharmacol. 38:699-702. If the VTP-receptor is coupled to G-proteins, this could explain the array of VIP effects found, as G-proteins are widespread and involved in several signal transduction pathways. VIP induces its own RNA in PC12 cells, probably as a result of its activation of adenylate cyclase. Tsukada et al. (1995) Mol. Cell. Endocrinol. 107:231-239. Regulation of VIP expression occurs also at a translational or post-translational level. Agoston et al. (1992). VIP may act as an autocrine regulator of its own synthesis.
  • VIP treatment produces a loss of responsiveness to subsequent rechallenges; a short-term exposure to VIP results in internalization of the receptor-peptide complex, a feature that may be tissue-specific.
  • VIP is degraded in lysosymes and may serve as an intracellular effector, while the receptors are recycled to the cell surface.
  • VIP binding sites and VIP-stimulated adenylate cyclase can be reduced by preincubation with different agents, although the different agents appear to function by different mechanisms.
  • the VIP receptor appears to be translocated to a light vesicle fraction after such exposure. In some cell lines, the half-life of the receptor was around 2 days, and N- glycosylation was necessary for translocation.
  • An internalized VIP receptor is dissociated from adenylate cyclase activity, although the internalization process is not co ⁇ letely independent of cAMP accumulation. Hejblum et al. (1988) Cancer Res. 48:6201-6210.
  • VIP signal transduction thus relies on multiple pathways other than elevation of cAMP. Neuropeptide
  • Neuropeptide Y is a 36-amino acid peptide neurotransmitter that is located throughout the central and peripheral nervous systems. Tatemoto (1982) Proc. Nati Acad. Sci. USA 79:5485; and Hazlewood (1993) Proc. Soc. Exp. Biol. Med. 202:44. It affects a broad range of phenomena, including blood pressure regulation, memory, anxiolysis/sedation, food and water appetite, vascular and other smooth muscle activity, intestinal electrolyte secretion, and urinaiy sodium excretion. Colmers and Wahlestedt, The Biology of Neuropeptide Y and Related Peptides (Humana Press, Totowa, NJ 1993).
  • Peptide YY (PYY) is also a 36 amino acid peptide and has significant sequence homology (70%) to NPY. Tatemoto et al. (1982) Nature 296:659. Its anatomical distribution is similar to that of NPY, although it is located mainly in the endocrine cells of the lower gastrointestinal tract. Bottcher et aL (1984) Regul. Pept. 8:261 (1984). Like NPY, PYY stimulates feeding in rats. Morley et aL (1985) Brain Res. 341 :200. Along with the pancreatic polypeptide (PP), NPY and PYY have a common tertiary structure, characterized by the so-called PP-fold. Glover (1985) Eur. X Biochem 142:379. Both NPY and PYY show about a 50% sequence homology with PP.
  • NPY and PYY have a number of comnr ⁇ n receptors. At least four receptor subtypes, Yl, Y2, Y3, and Y4 PP, have been identified. The affinity for NPY, PYY, and various fragments thereof varies among the subtypes. WO 95/17906.
  • NP encompasses all forms of neuropeptides with stenosis-inhibiting activity.
  • OBJECTS AND SUMMARY OF THE INVENTION The present invention encompasses a device containing a delivery system for implantation in a blood vessel or other biological lumen and a therapeutically effective amount a pharmaceutical agent.
  • the device is particularly useful for delivery of a pharmaceutical agent locally for instance of vasoactive intestinal peptide effective to treat stenosis in the blood vessel or proximal to a solid tumor to deliver chemotherapy directly to the vasculature of the tumor.
  • the delivery system can be any known in the art including, but not limited to, a stent.
  • the device need only be the general shape of a stent however in that it has a lumen and can be placed in a biologic lumen.
  • the device need not provide the rigidity of a stent as it is not necessarily provided to maintain the lumen size of an angioplasty stent.
  • the device can be, and preferably, is biodegradable or bioresorbable.
  • replacement as needed is provided.
  • a single stent with a drug delivery life of 3-6 months should be sufficient to treat restenosis.
  • a stent or similar device that is resorbed or degraded within this time would be sufficient.
  • replacement stents would ensure continuous treatment of the disease.
  • a device that could be resorbed or degraded and replaced every few months would greatly improve the treatment profile of these patient.
  • a biodegradable or bioresorbable catheter or stent provides the properties necessary for drug delivery according to the invention. If the stent is permanent, the pharmaceutical agent can be coated onto or impregnated into the stent. Numerous stents are known in the art, including, but not limited to, those discussed in the Background of the Invention. Additional suitable stents are mentioned for instance in US Patent Nos.
  • the device provided herein provides a drug eluting stent that inhibits intimal cell proliferation, reverses endothelial dysfimction, enhances the microcirculation and prevents or inhibits negative remodeling.
  • the device is suitable for use in treatment of decreased blood flow through a blood vessel such as is found in pulmonary hypertension, restenosis and diabetes.
  • the device is suitable for use in treating each of these indications.
  • angioplasty is more effective than thrombolytic therapy in reestablishing flow in acute/subacute myocardial infarction.
  • the device is suitable for use in treating pulmonary hypertension, acute/subacute infarction, or severe stenosis causing ischemia, the so- called rescue angioplasty.
  • the stent is suitable for use in treating any patient in danger of suffering stenosis of a blood vessel or pulmonary hypertension.
  • the device has many advantages over ordinary stents in ameliorating stenosis. Restenosis is induced by initial platelet adhesion and thrombus formation followed by immunocyte adhesions on the stent surface and injured vessel wall. The thrombus then releases factors that activate proliferation of smooth muscle cells.
  • the pharmaceutical agents employed with the device of the present invention elevate platelet cAMP levels and inhibit the platelet activation induced by platelet activating factor.
  • the device By administering the pharmaceutical agent directly to the site of stenosis, the device decreases side effects and allows for use of much lower drug concentrations than would be used in systemic administratioa Due to the nature of vasodilators such as VIP and NP, systemic administration would be contra-indicated in treating or preventing stenosis.
  • the device is suitable for use in delivering a chemotherapeutic agent to a tumor.
  • the device can be implanted in an artery that feeds the vasculature of the tumor. Thus, the device is implanted proximal to a tumor. This decreases systemic levels of chemotherapeutic agents and increases the concentration of agent delivered directly to the tumor.
  • Any suitable tumor can be treated including, but not limited to, astrocytoma, oligodendroglioma, epentfymoma, medulloblastoma, primitive neural ectodermal tumor (PNET), pancreatic ductal adenocarcinoma, small and large cell lung adenocarcinomas, squamous cell carcinoma, bronchoalveolarcarcinoma, epithelial adenocarcinoma, and liver metastases thereof hepatoma, cholangiocarcinoma, breast tumors such as ductal and lobular adenocarcinoma, squamous and adenocarcinomas of the uterine cervix, uterine and ovarian epithelial carcinomas, prostatic adenocarcinomas, transitional squamous cell carcinoma of the bladder, soft tissue sarcomas and leiomyosarcomas.
  • PNET neural ectoderma
  • the device is also useful for treating pancreatic disorders and can be placed in the pancreatic duct.
  • a biodegradable or bioresorbable device is preferred.
  • the device is also suitable for use when placed in other lumens including, but not limited to, ureter, urethra, bile duct and spinal column for deliver of pharmaceutical agents to these sites.
  • the dose of the pharmaceutical agent required to be administered to achieve the desired effect of improvement in the patient's condition will vary depending on several factors, including the severity of symptoms, size and health of the patient and elapsed time since onset of infarction, ischemia or angioplasty.
  • the preferred amount to be administered depends on the pharmaceutical agent, patient and the circumstances.
  • the appropriate dosage range is that which is large enough to produce amelioration but not so large as to induce unwanted side effects.
  • the required dosage can be determined by one of skill in the art.
  • the pharmaceutical agent is VIP
  • it is present in the range of from about 0.001 ⁇ g to 500 ⁇ g. More preferably, the VIP is present in an amount of from about 1 ⁇ g to 250 ⁇ g.
  • the pharmaceutical agent is NP
  • it is present in the range of from about 0.001 ⁇ g to 500 ⁇ g. More preferably, the NP is present in an amount of from about 1 ⁇ g to 250 ⁇ g.
  • the concentrations of one or both are adjusted accordingly. Any concentration of the named pharmaceutical agents effective to ameliorate (prevent, inhibit or treat) restenosis is encompassed by the invention.
  • 'NIP and ⁇ P refer to the native molecules and derivatives thereof.
  • VIP and ⁇ P encompass any natural or synthetic peptide that is substantially similar to the native peptide and retains native activity even though the peptide may have been manipulated, genetically or otherwise, to alter or enhance that activity.
  • substantially similar means a peptide in which amino acid residues non-essential to the stenosis-inhibition activity of the peptide have been altered in an attempt to alter or enhance that activity, but the peptide still retains a high level of amino acid residue sequence similarity to the native peptide.
  • VTP is advantageous because it is a vasodilator; a vasorelaxant (it decreases systemic vascular resistance (SVR)); an anti- inflammatory, it inhibits mitogen induced T lymphocyte proliferation; inhibits cytokine release; decreases Interleukin-2 production; inhibits vascular smooth muscle cell growth; and enhances endothelial constitutive nitric oxide synthetase (ecNOS) an enzyme for generating nitric oxide (NO) in endothelial cells.
  • SVR systemic vascular resistance
  • ecNOS endothelial constitutive nitric oxide synthetase
  • NP is advantageous because it is a potent vasodilator (200 times more than prostacyclin); a vasorelaxant; an anti-inflainmatory, and inhibits mitogen induced The lymphocyte proliferation; inhibits cytokine release; decreases Interleukin-2 production; enhances ecNOS; inhibits platelet aggregation increasing cAMP in platelets and therefore lessens platelet aggregation. It also lessens platelet aggregation by inhibiting phospholipase A2 activity.
  • Suitable chemotherapeutic agents include, without limitation, vinca alkaloids such as the vinblastine, vincristine and vindesine sulfates, adriamycin, bleomycin sulfate, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, duanorubicin hydrochloride, doxorubicin hydrochloride, etoposide, fluorouraciL lomustine, mec orore amine hydrochloride, melphalan, mercaptopurine, methotrexate, rdtomycin, mitotane, pentostatin, pipobroman, procarbaze hydrochloride, streptozotocin, taxol, thioguanine, uracil mustard and anti- cancer antibodies.
  • vinca alkaloids such as the vinblastine, vincristine and vindesine sulfates,
  • “Amelioration” means any improvement in the condition of the patient that has occurred as a result of adm-nistration of treatment with the claimed invention. This includes any increase in survival time over what would have previously been expected. In a patient responding particularly well there should be some restoration of effective cardiac function. It does not mean a complete cure or prevention of all restenosis although this is what is aimed for.
  • a "patient” is a vertebrate, preferably mammal, more preferably human. Mammals including, but not limited to, humans, farm animals, sport animals and pets. Preferably, the patient is human Suitable patients for treatment with this invention are those suffering from arterial stenosis arising by any means.
  • the pharmaceutical agents can be delivered by the delivery system by any method known in the art.
  • the agent can be coated or adsorbed on the delivery system Any biocompatible coating known in the art, including, but not limited to, those discussed in the Background of the Invention, can be used provided it releases the pharmaceutical agent in atherapeutically effective manner.
  • the biocompatible coatings are typically polymers with their tertiary structure acting as a depot for a drug to be held and released by the characteristics of the coating or elution of the drug from a coating. Suitable coatings also include saccharides and po-ysaccharides. Numerous coatings and solid dose delivery compositions are provided by Roser et al. WO 96/03978.
  • the device is biodegradable or bioresorbable and allows for near zero order release rate of the agent.
  • Suitable materials for use in making or coating the device include, without limitation, reducing, non-reducing and hydrophobically derivatized carbohydrates.
  • Reducing carbohydrates include, without limitation glucose, maltose, lactose, fructose, galactose, mannose, maltulose, iso-maltulose and lactulose.
  • Non-reducing carbohydrates include, without limitation, trehalose, raffinose, stachyose, sucrose and dextran.
  • Other useful carbohydrates include non-reducing glycosides of polyhydroxy compounds selected from sugar alcohols and other straight chain po /alcohols.
  • the sugar alcohol glycosides are preferably monogtycosides, in particular the compounds obtained by reduction of disaccharides such as lactose, maltose, lactulose and maltulose.
  • Hydrophobically derivatized carbohydrates refer to a wide variety of carbohydrates where at least one hydroxyl group is substituted with a hydrophobic moiety including, but not limited to, esters and ethers. Numerous examples of suitable carbohydrates and their syntheses are described in Developments in Food Carbohydrate -2 ed. CK. Lee, Applied Science Publishers, London (1980). Other syntheses are described for instance, in Akoh et al. (1987) X Food Sci. 52:1570; Khan et aL (1993) Terra.
  • Such carbohydrates include, without limitation, sorbitol hexaacetate, ⁇ -glucose pentaacetate, ⁇ -glucose pentaacetate, 1-0-Octyl- ⁇ -D-glucose tetraacetate, trehalose octaacetate, and di-0- methyl-hexa-0-acetyl sucrose. Whichever method is used coating or impregnation of pharmaceutical agent, it should allow slow release of atherapeutically effective amount of the pharmaceutical agent for a therapeutically effective length of time.
  • the pharmaceutical agents can also be bonded onto the surface of the delivery system and released by chemical interaction with the blood and its components or other physiologic fluids.
  • the pharmaceutical agent can be formulated with other physiologically acceptable components.
  • Such formulations can contain appropriate non-toxic and non-interfering components.
  • Such components including, but not limited to, liquid excipients, medicinal agents, pharmaceutical agents, carriers and substances such as wetting or emulsifying agents and pH buffering agents.
  • Liquid excipients including, but not limited to, water, saline glycerol or ethanol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne des dispositifs d'apport de médicament par voie intraluminale. Le dispositif, tel qu'un stent, est revêtu ou imprégné d'un agent pharmaceutique approprié pour être utilisé dans le traitement de la resténose, de l'hypertension pulmonaire et du cancer. Les agents pharmaceutiques appropriés peuvent être des vasodilatateurs et des substances chimiothérapeutiques.
EP03757429A 2002-06-10 2003-06-10 Dispositif medical permettant l'apport intraluminal d'agents pharmaceutiques Withdrawn EP1551334A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US166059 1988-03-23
US16605902A 2002-06-10 2002-06-10
PCT/US2003/018059 WO2003103743A2 (fr) 2002-06-10 2003-06-10 Dispositif medical permettant l'apport intraluminal d'agents pharmaceutiques

Publications (2)

Publication Number Publication Date
EP1551334A2 true EP1551334A2 (fr) 2005-07-13
EP1551334A4 EP1551334A4 (fr) 2006-12-13

Family

ID=29732103

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03757429A Withdrawn EP1551334A4 (fr) 2002-06-10 2003-06-10 Dispositif medical permettant l'apport intraluminal d'agents pharmaceutiques

Country Status (5)

Country Link
EP (1) EP1551334A4 (fr)
JP (1) JP2005528956A (fr)
AU (1) AU2003243439A1 (fr)
CA (1) CA2489282A1 (fr)
WO (1) WO2003103743A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
EP1986735A4 (fr) 2006-02-06 2011-06-29 Northwind Ventures Systèmes et procédés de réduction de volume
US8404281B2 (en) 2009-06-08 2013-03-26 Avant Garde Therapeutics & Technologies Llc Formulations
WO2011056578A2 (fr) 2009-10-26 2011-05-12 Cardiokinetix, Inc. Réduction du volume ventriculaire
US20140328933A1 (en) * 2010-06-16 2014-11-06 Shaker Mousa Novel formulations and methods
WO2013090848A1 (fr) * 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Appareil et procédés de traitement de l'hypertension pulmonaire
AU2015321690A1 (en) 2014-09-28 2017-03-23 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039103A1 (fr) * 1995-06-06 1996-12-12 Quanam Medical Corporation Extenseur intravasculaire
WO2001085218A2 (fr) * 2000-05-11 2001-11-15 Eastman Chemical Company Cyclodextrine acylee: complexes d"inclusion de molecule incluse
WO2003030943A1 (fr) * 2001-10-09 2003-04-17 The University Of British Columbia Compositions comprenant hydroxyapatite utilisees pour administrer des agents therapeutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039103A1 (fr) * 1995-06-06 1996-12-12 Quanam Medical Corporation Extenseur intravasculaire
WO2001085218A2 (fr) * 2000-05-11 2001-11-15 Eastman Chemical Company Cyclodextrine acylee: complexes d"inclusion de molecule incluse
WO2003030943A1 (fr) * 2001-10-09 2003-04-17 The University Of British Columbia Compositions comprenant hydroxyapatite utilisees pour administrer des agents therapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRASE L L ET AL: "Cardiovascular effects of vasoactive intestinal peptide in healthy subjects." THE AMERICAN JOURNAL OF CARDIOLOGY. 1 DEC 1987, vol. 60, no. 16, 1 December 1987 (1987-12-01), pages 1356-1361, XP002404699 ISSN: 0002-9149 *
See also references of WO03103743A2 *

Also Published As

Publication number Publication date
WO2003103743A2 (fr) 2003-12-18
EP1551334A4 (fr) 2006-12-13
AU2003243439A1 (en) 2003-12-22
CA2489282A1 (fr) 2003-12-18
JP2005528956A (ja) 2005-09-29
WO2003103743A3 (fr) 2004-07-22
AU2003243439A8 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
US9216239B2 (en) Medical device for intra-lumenal delivery of pharmaceutical agents
EP1551334A2 (fr) Dispositif medical permettant l'apport intraluminal d'agents pharmaceutiques
JP5153340B2 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
Rogers et al. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration.
DE602004004331T2 (de) Implantierbare Pumpe zur Behandlung von Fettleibigkeit
US5244460A (en) Method to foster myocardial blood vessel growth and improve blood flow to the heart
JP6005899B2 (ja) 薬剤を分散させるための医療器具
US8187223B2 (en) Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis
Modlin et al. Experimental evidence for vasoactive intestinal peptide as the cause of the watery diarrhea syndrome
ES2223774T3 (es) Dispositivo medico.
AU2009268480C1 (en) Delivery of dry formulations of octreotide
JP2003501151A (ja) 動脈再狭窄治療用装置および化合物
Buchwald et al. Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs.
JP2000502682A (ja) 血管新生を促進する成長因子の局所的血管内デリバリー
TW200306826A (en) Drug delivery systems for the prevention and treatment of vascular diseases
US8709465B2 (en) Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
JP2006519623A (ja) タンパクチロシンキナーゼインヒビターで被覆されたまたは含浸された血管ステントまたは血管グラフト、およびその使用方法
US20080085293A1 (en) Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
CN101378775A (zh) 对人促生长素抑制素受体亚型具有不同选择性的促生长素抑制素类似物的组合
Bartorelli et al. Local heparin delivery prior to coronary stent implantation: acute and six‐month clinical and angiographic results
CN101309706A (zh) 药剂释放控制组合物及药剂释放性医疗器具
US8771310B2 (en) Anti-no-reflow guide wire for vascular interventional procedures
WO2001070295A1 (fr) Stent coronarien enduit d'un antagoniste de recepteur d'endotheline
US20050273177A1 (en) Prosthetic device having drug delivery properties
US20130337053A1 (en) Novel formulations and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050107

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20061110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070102